EMA Authorised: Tuzulby (methylphenidate hydrochloride) — Neuraxpharm Pharmaceuticals S.L.

View source ↗

Summary

The EMA authorised Tuzulby (methylphenidate hydrochloride) for attention-deficit/hyperactivity disorder in the European Union, with Neuraxpharm Pharmaceuticals …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Tuzulby (methylphenidate hydrochloride)

Snippet

Status: Authorised. Therapeutic area: Attention Deficit Disorder with Hyperactivity. MAH: Neuraxpharm Pharmaceuticals S.L.. Decision date: 19/12/2025